RxDoctor Payments Data

Julie Denton, NP

Psychiatric/Mental Health · Greenwood, INNPI 1629486626

Payments from drug & device makers

$2,731in general payments, 2019–2025

Across 88 payments — averaging $31.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$510
  • Otsuka America Pharmaceutical, Inc.$457
  • AbbVie$450
  • Johnson & Johnson$359
  • Neurocrine Biosciences, Inc.$318
  • Teva Pharmaceuticals USA, Inc.$164
  • plus $474 from 6 others

What the payments were for

  • Food & beverage$2,731100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,731 in reported general payments places this provider in the 80th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$10,487
Medicare patients
37
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate71$205,685
Invega TrinzaPaliperidone Palmitate14$153,257
Abilify MaintenaAripiprazole36$106,787
PerserisRisperidone21$54,240
AristadaAripiprazole Lauroxil16$50,618
Paliperidone ErPaliperidone83$13,881
Clozapine55$8,254
Lurasidone Hcl29$7,349
Aripiprazole75$4,931
Olanzapine84$4,405
Divalproex Sodium38$3,953
Ramelteon18$2,264
Divalproex Sodium ErDivalproex Sodium32$2,142
Quetiapine Fumarate ErQuetiapine Fumarate53$1,690
Ziprasidone Hcl16$1,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$359$358,94285 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$457$106,78736 claims
Indivior Inc.Perseris$41$54,24021 claims
Alkermes, Inc.Aristada$510$50,61816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Greenwood

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →